Sean Liew

Title: Sean Liew: Innovator in ACC Inhibitor Development

Introduction

Sean Liew is a notable inventor based in Edmonton, Canada. He has made significant contributions to the field of pharmaceutical sciences, particularly in the development of compounds that exhibit inhibitory activity against Acetyl-CoA carboxylase (ACC). His work is crucial for advancing treatments for ACC-mediated diseases.

Latest Patents

Sean Liew holds a patent for "Processes for preparing ACC inhibitors and solid forms thereof." This patent details the provision of solid forms, including salts or co-crystals, of a compound that demonstrates ACC inhibitory activity. The processes outlined in the patent are essential for preparing the compound and its intermediates, which are useful in the treatment of various diseases.

Career Highlights

Sean Liew is currently employed at Gilead Sciences, Inc., a leading biopharmaceutical company. His role involves research and development focused on innovative therapeutic solutions. With a patent portfolio that includes 1 patent, he has established himself as a key contributor to the field.

Collaborations

Throughout his career, Sean has collaborated with esteemed colleagues, including Michael Geier and Norihiro Ikemoto. These collaborations have enhanced the research and development efforts at Gilead Sciences, Inc., fostering innovation in the pharmaceutical industry.

Conclusion

Sean Liew's work in developing ACC inhibitors showcases his commitment to advancing medical science. His contributions are vital for the ongoing research in treating ACC-mediated diseases, and his innovative spirit continues to inspire others in the field.